Portable, Point-of-Care Solution
By leveraging the principles of Raman Spectroscopy, Seraspec® represents a paradigm shift away from current methods for screening and identification of dangerous bacterial, viral and fungal pathogens. Our patent pending technology and method of detection* effectively eliminates the need for time-consuming and costly laboratory-based methods of specimen collection, processing and pathogen identification. Safety, efficiency, accuracy and profitability are simultaneously enhanced through a portable, point-of-care technology for real-time pathogen detection and identification. A higher power just got involved in the fight against infection.
A Molecular Fingerprint
Reagentless, Fully-Automated Detection
The Seraspec® employs an enclosed assembly of optical components allowing for real-time Raman spectral measurements that generate a unique molecular fingerprint for pathogen identification. The system also incorporates proprietary signal processing and identification algorithms to distinguish targeted pathogens from confounding background interference facilitating real-time identification at the point-of-care. This disruptive technology will enable health care providers to render more efficient healthcare decisions and optimize clinical outcomes.
Healthcare faces a daunting global crisis resulting from the convergence of accelerating antimicrobial resistance and novel pandemic viruses. Acting swiftly to treat infections with broad-based antibiotics appears prudent when the alternative is laboratory-based verification spanning several days. This “shotgun” approach essentially guarantees that the antimicrobial resistance crisis will continue to escalate.
Our mission as a company is to produce quality, cost-effective technologies for health care providers to optimize clinical decision making in our globally integrated society. With the right tools and partners, we hope and believe that this crisis will be averted.
Chief Executive Officer
Jim serves as Chief Executive Officer of Seraph Biosciences bringing over 20 years of executive management, sales, and marketing experience. Jim began his career as President & Chief Operating officer of Rootlevel, Inc. where he established the company as one of the Midwest’s leading web application firms. Jim also served as Executive Vice President & Managing Director of Picnic New Media for Ringside Creative and Cutters Studios where he lead the interactive and mobile development efforts. Prior to joining Seraph Biosciences, served as Chief Marketing Officer of Medical Engineering Partners, LLC.
Chief Operations Officer
Braden serves as Chief Operations Officer of Seraph Biosciences bringing over 19 years of experience in medical devices. He has launched more than one hundred products through the FDA regulated process. As Senior Director of Business Development and Strategy for Stryker Corp., he successfully led $235M worth of transactions and started 2 different divisions for the company. Prior to joining Seraph Biosciences, Braden served as a Mentor-in-Residence at the University of Michigan’s Tech Transfer program and principal of 1021 Partners aimed at helping early stage companies build and grow their businesses.
Gregory W. Auner, PhD
Founder & Chief Science Officer
Dr. Auner is a co-founder and Chief Science Officer of Seraph Biosciences. He holds the Strauss TEAMS Endowed Chair and is a Professor of Electrical and Computer Engineering, Biomedical Engineering, and Material Science at Wayne State University. He is also the founder and Director of the Smart Sensors and Integrated Microsystems Program. Dr. Auner has over 30 patents (issued and pending) in the last few years for chemical, biomedical, and environmental sensors and microsystems and has been granted more than $35 million in research grants and contracts as principle investigator. Along with co-founding Seraph Biosciences, he is the Chief Technology Officer and Co-Founder of Visca, LLC, and Medical Engineering Partners, LLC
Vice President - Product Development
Mr. Sayegh brings over 30 years of experience in the development of clinical, veterinary, and agricultural immunodiagnostics. As an executive and director, he has led teams of seasoned senior scientists and technicians in the successful development and commercialization of over 30 diagnostic tests for various applications including infectious disease, tumor markers, and drugs of abuse. Mr. Sayegh has also managed the design control process, validation, and commercialization of over 12 FDA-regulated clinical diagnostic tests involving 510(k) and PMA submissions. Prior to joining Seraph Biosciences, Mr. Sayegh served as the Associate Director of Diagnostics for Zoetis.
Vice President - Engineering
Shane Trexler serves as Vice President of Engineering for Seraph Biosciences, Inc. drawing upon 10 plus years of laboratory research, engineering design, and business management. As the founder and president of the Sustainable Consulting Group, Shane successfully managed engineering design efforts for both startup companies and established medical device and engineering clients throughout the United States as well as Eastern Africa. He has consulted in the design, development, and prototypes of components and systems for various medical device companies.
Director - Cloud & Software Engineering
Naga Puttagunta serves as Director of Cloud & Software Engineering for Seraph Biosciences, Inc. with over 20 years of experience in commercial software development, cloud architecture, and data security systems. Most recently, Naga served as Vice President of Software Engineering for Aptiv, a publicly traded automotive parts company specializing in systems development for signal and power solutions as well as advanced safety and user experience in mobility. In addition to his technical expertise, Naga has a proven track record of establishing, growing, and leading large software teams.
Ehsan Majidi, PhD
Senior Research Scientist - Software
Dr. Majidi serves as a Senior Software Engineer for Seraph Biosciences, Inc. He is charged with writing and implementing Seraph’s proprietary algorithms, which are foundational to Seraspec’s automated diagnostic software. Prior to joining Seraph Biosciences, Dr. Majidi was a Senior Software Engineer for Delphi Automotive and Senior Software Engineer and researcher in autonomous vehicles for General Motors. He earned his doctorate from Wayne State University’s College of Engineering specializing in software development, deep learning, and neural networks.
Advanced Quality Engineer
Lamees Almawri serves as an Advanced Quality Engineer for Seraph Biosciences, Inc. She is responsible for executing Seraspec’s Quality System with the management team as well as the company’s external suppliers. Lamees holds a BS in Biological Sciences from the University of Michigan-Dearborn and an MS in Biomedical Engineering from Wayne State University. She has a combined 4 years of research experience at Beaumont Health and Henry Ford Health System and 3 years of quality and testing experience in the medical device industry at Stryker Instruments and Healthmark Industries.
Charles J. Shanley, MD
Founder & Chairman
Dr. Shanley is a co-founder and Chairman of Seraph Biosciences, Inc. He currently serves as President and Chief Executive Officer of Wayne State University Physician Group and Vice Dean of Clinical Affairs at Wayne State University’s School of Medicine. Dr. Shanley also serves on the Health Care Patient Safety and Quality Study Section of the Agency for Health Care Research and Quality (AHRQ) and was appointed to the Circulatory Devices Advisory Panel at the FDA. Dr. Shanley’s research has been funded by the U.S. Army Telemedicine and Advanced Technology Research Center (TATRC); the Michigan Economic Development Corporation (MEDC) and the National Institutes of Health (NIH).
CEO, Jack Entertainment LLC
Matthew Cullen is a highly respected Detroit business leader. In his various leadership roles, he has helped oversee $5.6 billion in acquisition and development of more than 100 properties in downtown Detroit and Cleveland. Mr. Cullen also serves as the founding Chair of the Detroit Riverfront Conservancy, voluntary Chief Executive Officer of the Detroit’s Q-Line / M-1 Rail, and the former Chief Executive Officer of Bedrock in Detroit.
President, MFS & Co.
Michael Shields is a successful entrepreneur, business leader, and mentor. He currently serves as Chief Executive Officer of Novation Analytics, where he oversees the strategic direction of the company in becoming a premier provider of software and data solutions to the automotive industry. Prior to his current appointment, Mr. Shields served as CEO, Founder, and majority owner of Control-Tec, LLC, a powertrain control systems technology provider. Over the past 10 years, Mr. Shields held a variety in the leadership positions in Arrow Racing Engines, LLC, Arrow Performance Products, LLC, Power-Tec, LLC, Saleen, LLC and Cyltec, LLC and served as President of Flat Rock Metal, Inc. and Bar Processing, LLC. He is also the Greater Detroit Chapter Chair of the Young Presidents Organization (YPO).
Chairman, Emagine Entertainment
Paul Glantz currently serves as Founder and Chairman of Emagine Entertainment, Inc. As part of Emagine Entertainment, Emagine theaters were identified by the Detroit News as the “Best Theaters in Michigan” for three years running. Mr. Glantz also acts as Chief Executive Officer of Proctor Financial Inc., a provider of specialized insurance services to mortgage servicers nationwide. In addition to his business activities, Mr. Glantz serves as a director of Gleaners Community Food Bank of Southeastern Michigan, member and investment committee chairman of the Wayne State University Foundation, and treasurer of the Detroit Chapter of Variety International.
Scott Merz, PhD
CEO, MC3 Cardiopulmonary
Dr. Merz is a co-founder and Chief Executive Officer of MC3 Cardiopulmonary, a company that commercializes intellectual property related to artificial heart and lung technologies. Dr. Merz has over 25 years of experience in medical device research, development, and business formation. He holds over 10 patents and has led numerous licensing deals enabling the launch of several spinout medical device companies. He is a charter member of the Extracorporeal Life Support Organization (ELSO) and long-standing leader of the cardiopulmonary community.
Gary Loveman, PhD
Professor, Harvard Business School
Dr. Loveman is currently a Senior Lecturer in the Department of Finance at Harvard Business School. He previously served as Chairman, CEO and President of Caesars Entertainment Corporation. During his seventeen year tenure, Dr. Loveman oversaw the expansion of Caesars into the largest and most diversified company in the gaming industry. He also pioneered Caesar’s Wellness Rewards, an incentive-based health and wellness program for over 70,000 employees and their families. Dr. Loveman recently served as President of Consumer Health and Service at Aetna Inc. where he led the company’s population health, consumer engagement and clinical services areas.
Founder & COO, Medical Engineering Partners
Mr. Trexler is a co-founder of Seraph Biosciences and helps manage the day to day operations, including the strategic and operational planning activities required to help launch the company. He earned his BS degree in Chemical Engineering and an MBA with a concentration in finance. Mr. Trexler started his entrepreneurial career over twenty years ago by founding Technical Enviro Services, Inc. He currently serves as Chief Executive Officer of Technical Enviro Services and Chief Operating Officer of Medical Engineering Partners, LLC.